1,210
Views
10
CrossRef citations to date
0
Altmetric
HEMATOLOGICAL MALIGNANCY

Bone marrow fibrosis may be an effective independent predictor of the ‘TKI drug response level’ in chronic myeloid leukemia

, , , , , , , , , & show all

References

  • Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–84.
  • Haznedaroglu IC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opin Pharmacother. 2013;14:2005–10.
  • Sayinalp N, Cinar H, Uner A, Haznedaroglu IC, Buyukasik Y, Goker H, et al. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders. Clin Lab Haematol. 2004;26:265–8.
  • Cobankara V, Oran B, Ozatli D, Haznedaroglu IC, Kosar A, Buyukasik Y, et al. Cytokines, endothelium, and adhesive molecules in pathologic thrombopoiesis. Clin Appl Thromb Hemost. 2001;7:126–30.
  • Bennour A, Tabka I, Ben Youssef Y, Kmeria Z, Khelif A, Saad A, et al. A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy. Cancer Biol Med. 2013;10:47–51.
  • Karimata K, Masuko M, Ushiki T, Kozaki T, Shibasaki Y, Yano T, et al. Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Intern Med. 2011;50:481–5.
  • Navarro JT, Feliu E, Grau J, Espiret B, Colomer D, Ribera JM, et al. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol. 2007;82:849–51.
  • Pitini V, Arrigo C, Sauta MG, Altavilla G. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. Leuk Res. 2009;33:e143–4.
  • Uz B, Tatonyan SC, Sayitoglu M, Erbilgin Y, Ng OH, Buyukasik Y, et al. Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders. J Renin Angiotensin Aldosterone Syst. 2013;14:308–14.
  • Uz B, Buyukasik Y, Atay H, Kelkitli E, Turgut M, Bektas O, et al. EUTOS CML prognostic scoring system predicts ELN-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology 2013;18:247–52.
  • Lugli A, Ebnoether M, Cogliatti SB, Gratwohl A, Passweg J, Hess U, et al. Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. Hum Pathol. 2005;36:91–100.
  • Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Höfler G, Haas OA, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99:381–3.
  • Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, et al. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia. Leukemia 2004;18:1460–67.
  • Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007;21:2420–27.
  • Buesche G, Georgii A, Duensing A, Schmeil A, Schlue J, Kreipe HH. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol. 2003;34:391–401.
  • Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial. Leukemia 2003;17:2444–53.
  • Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004;101:332–6.
  • de Jesus CR, I-Ching L, Carvalho Neiva TdJ, Vituri CdL. Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response. Braz J Pharm Sci. 2011;47:313–22.
  • Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, et al. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. Am J Clin Pathol. 2003;119:833–41.
  • Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderi S, et al. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 2005;104:777–80.
  • Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, et al. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 2005;46:993–7.
  • Khonglah Y, Basu D, Dutta TK. Bone marrow trephine biopsy findings in chronic myeloid leukemia. Malays J Pathol. 2002;24:37–43.
  • Ahmed A, Powers MP, Youker KA, Rice L, Ewton A, Dunphy CH, et al. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study. Pathol Res Pract. 2009;205:634–8.
  • Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009;28:1285–97.
  • Mahadevan KK, Basu D, Kumar S. Does CD34 staining reflect the angiogenic process in the bone marrow? An analysis of a series of chronic myeloid Leukemia patients. J Clin Diagn Res. 2014;8:FC04–7.
  • Rao S, Sen R, Singh S, Ghalaut PS, Arora BB. Grading of marrow fibrosis in chronic myeloid leukemia – a comprehensive approach. Indian J Pathol Microbiol. 2005;48:341–4.
  • Shirai K, Sera Y, Bulkeley W, Mehrotra M, Moussa O, LaRue AC, et al. Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Exp Hematol. 2009;37:1464–71.
  • Srinivas BH, Paul TR, Uppin SG, Uppin MS, Jacob RT, Raghunadharao D. Morphologic changes in the bone marrow in patients of chronic myeloid leukemia (CML) treated with imatinibmesylate. Indian J Hematol Blood Transfus. 2012;28:162–9.
  • Valent P, Agis H, Sperr W, Sillaber C, Horny HP. Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. Leuk lymphoma 2008;49:635–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.